ReviewFrontiers in immunology2015
The Ins and Outs of B Cells in Multiple Sclerosis.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions.International journal of molecular sciences · 2025Pooled it
- Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.Neurology(R) neuroimmunology & neuroinflammation · 2020Trial
- A potential of serum anti-C1P IgG antibodies as biomarkers in differential diagnosis of relapsing-remitting multiple sclerosis.Scientific reports · 2026Article
- Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers.Inflammopharmacology · 2025Review
- Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.Neuropsychopharmacology reports · 2025Review
- CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.Journal of neurology · 2025Review
- Tertiary Lymphoid Structures in Central Nervous System Disorders.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Hematopoietic stem cell transplantation for multiple sclerosis: no inflammation, no response.European journal of neurology · 2025Article
- Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Intrathecal B cell-related markers for an optimized biological investigation of multiple sclerosis patients.Scientific reports · 2022Article
- Article
- Cleavage-free human genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy.Frontiers in neurology · 2022Article
- Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.Journal of neurology · 2021Review
- Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.PLoS pathogens · 2021Article
- Article
- The role of B cells in the immunopathogenesis of multiple sclerosis.Immunology · 2020Review
- Pathology of inflammatory diseases of the nervous system: Human disease versus animal models.Glia · 2020Review
- Spatio-temporal expression profile of NGF and the two-receptor system, TrkA and p75NTR, in experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
B cells play a central role in multiple sclerosis (MS) pathology. B and plasma cells may contribute to disease activity through multiple mechanisms: antigen presentation, cytokine secretion, or antibody production. Molecular analyses of B cell populations in MS patients have revealed significant overlaps between peripheral lymphoid and clonally expanded central nervous system (CNS) B cell populations, indicating that B cell trafficking may play a critical role in driving MS exacerbations. In this review, we will assess our current knowledge of the mechanisms and pathways governing B cell migration into the CNS and examine evidence for and against a compartmentalized B cell response driving progressive MS pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.